- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
The role of carbohydrate moiety on the disposition of recombinant human granulocyte colony-stimulating factor (rGCSF). (1). Using deglycosylated-rGCSF and rG-CSF from E. coli.
-
- OKANO Ken
- Drug metabolism and Pharmacokinetics Research Labs., Chugai Pharmaceutical Co., LTD.
-
- KATO Motohiro
- Drug metabolism and Pharmacokinetics Research Labs., Chugai Pharmaceutical Co., LTD.
-
- AMANO Jun
- Drug metabolism and Pharmacokinetics Research Labs., Chugai Pharmaceutical Co., LTD.
-
- HIRAMATSU Yuka
- Drug metabolism and Pharmacokinetics Research Labs., Chugai Pharmaceutical Co., LTD.
-
- KINOSHITA Haruki
- Drug metabolism and Pharmacokinetics Research Labs., Chugai Pharmaceutical Co., LTD.
-
- OKAZAKI Akira
- Drug metabolism and Pharmacokinetics Research Labs., Chugai Pharmaceutical Co., LTD.
Bibliographic Information
- Other Title
-
- 遺伝子組換え型ヒトか粒球コロニー形成刺激因子(rG・CSF)の体内動態における糖鎖の役割 (1) 脱糖鎖型rG・CSFおよび大腸菌産生rG‐CSFを用いた検討
Search this article
Description
rG·CSF is a recombinant human granulo cyte colony-stimulating factor (rhG-CSF) produced in CHO cells. rG·CSF is a glycoprotein which has one O-linked sugar chain. We have studied the role of this sugar chain on the disposition of rG·CSF using enzymatically deglycosylated rG·CSF (degly-rG·CSF) and rhG-CSF produced in E. coli (Eco-rG-CSF).<BR> 1. rG·CSF or degly-rG·CSF was administered to rats at the dose of 10μg/kg intravenously and subcutaneously. After intravenous administration, the pharmacokinetic parameters (T1/2 (α), T1/2 (β), MRT, Vc and Vss) of two G-CSFs were not significantly different between each other except that the AUC in rG·CSF was greater and the CLtotal in rG·CSF was smaller than those in degly-rG·CSF. After subcutaneous administration, T1/2 and MRT in degly-rG·CSF were significantly smaller than those parameters in rG·CSF. Mean absorption time (MAT) and absolute bioavailability (F) in degly-rG·CSF were smaller than those in rG·CSF.<BR> 2. rG·CSF or Eco-rG-CSF was administered to rats at the dose of 10μg/kg intravenously and subcutaneously. After intravenous administration, the pharmacokinetic parameters of two G-CSFs were not significantly different between each other except that the AUC in rG·CSF was greater and the CLtotal in rG·CSF was smaller than those in Eco-rG-CSF. After subcutaneous administration, T1/2, MRT and AUC in Eco-rG-CSF were significantly smaller than those parameters in rG·CSF, respectively. MAT and F in Eco-rG-CSF were smaller than those in rG·CSF.<BR> 3. These results showed that after intravenous administration, there were little changes related to sugar chain. These results also suggested that sugar chain contributed to stabilization of rG·CSF at the administration site and delayed absorption of rG·CSF from the administration site after subcutaneous administration. Thus, the sugar chain of rG·CSF seemed to play a role in the elongation of plasma concentration after subcutaneous administration.
Journal
-
- Drug Metabolism and Pharmacokinetics
-
Drug Metabolism and Pharmacokinetics 8 (6), 1181-1190, 1993
The Japanese Society for the Study of Xenobiotics
- Tweet
Details 詳細情報について
-
- CRID
- 1390282679645290240
-
- NII Article ID
- 130003561598
-
- ISSN
- 09161139
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed